Tauritmo 25mg capsule

• Treatment of (Acute Myeloid Leukemia) Blood cancer

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of Tauritmo 25mg Capsule   include:

• Febrile neutropenia
• Nausea
• Vomiting
• Headache
• Petechiae (red or purple spot caused by bleeding into the skin)
• Musculoskeletal (bone, muscle or joint) pain
• Nosebleeds
• Infection
• Increased glucose level in blood
• Upper respiratory tract infection
• Mucositis

• Doctor determines the exact dose and duration with Tauritmo 25mg Capsule as per the overall health condition of the patient. This capsule should be taken with food or after food, but at the fix time every day to get effective results.
• Don't miss a dose or overdose on the medicine. Swallow it as a whole with a glass of water and do not crush, chew, or open it.​
  

• Tauritmo 25mg Capsule is an oral anticancer medicine with Midostaurin as an active ingredient. It belongs to the class of drugs known as multi-targeted kinase inhibitor.
• It works by inhibiting the action of abnormal protein that promote the uncontrolled growth of cancer cells. As a result, it stops the growth of cancerous cells and slows down the progression of cancer.​​
  

• Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., ... & Döhner, H. (2017). Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England Journal of Medicine, 377(5), 454-464. https://pubmed.ncbi.nlm.nih.gov/28644114/
• Gallogly, M. M., & Lazarus, H. M. (2016). Midostaurin: an emerging treatment for acute myeloid leukemia patients. Journal of blood medicine, 73-83. https://pubmed.ncbi.nlm.nih.gov/27186148/
• Abbas, H. A., Alfayez, M., Kadia, T., Ravandi-Kashani, F., & Daver, N. (2019). Midostaurin in acute myeloid leukemia: an evidence-based review and patient selection. Cancer management and research, 8817-8828. https://pubmed.ncbi.nlm.nih.gov/31632141/
• Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., ... & Reiter, A. (2016). Efficacy and safety of midostaurin in advanced systemic mastocytosis. New England Journal of Medicine, 374(26), 2530-2541. https://pubmed.ncbi.nlm.nih.gov/27355533/
• Kim, E. S. (2017). Midostaurin: first global approval. Drugs, 77(11), 1251-1259.